Role of flow cytometry of peripheral blood and bone marrow aspirates in early myeloma

Seminars in Hematology

Volumn 48, Issue 1, 2011, Pages 32-38

  Yuan, Constance M ^a   Stetler Stevenson, Maryalice ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CANCER REGRESSION; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; LYMPHOMA; LYMPHOPLASMACYTIC LYMPHOMA; MINIMAL RESIDUAL DISEASE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PLASMA CELL; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SMOLDERING MULTIPLE MYELOMA;

BONE MARROW; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; SUCTION;

EID: 78650965968     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2010.11.005     Document Type: Article

References (52)

1. Paiva B., Almeida J., Perez-Andres M., et al. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry 2010, 78B:239-252.
2. Nadav L., Katz B.Z., Baron S., et al. Diverse niches within multiple myeloma bone marrow aspirates affect plasma cell enumeration. Br J Haematol 2006, 133:530-532.
3. Paiva B., Vidriales M.B., Perez J.J., et al. Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. Haematologica 2009, 94:1599-1602.
4. Rawstron A.C., Orfao A., Beksac M., et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008, 93:431-438.
5. Davis B.H., Holden J., Bene M.C., et al. 2006 Bethesda international consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: medical indications. Cytometry 2007, 72B:S5-S13.
6. Kyle R.A., Durie B.G., Rajkumar S.V., et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010, 24:1121-1127.
7. Mateo G., Montalban M.A., Vidriales M.B., et al. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol 2008, 26:2737-2744.
8. Ocqueteau M., Orfao A., Almeida J., et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol 1998, 152:1655-1665.
9. Almeida J., Orafo A., Ocqueteau M., et al. High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. Br J Haematol 1999, 107:121-131.
10. Konoplev S., Medeiros L.J., Bueso-Ramos C.E., Jorgensen J.L., Lin P. Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia. Am J Clin Pathol 2005, 124:414-420.
11. Lin P., Owens R., Tricot G., Wilson C.S. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 2004, 121:482-488.
12. Witzig T.E., Kimlinger T., Stenson M., et al. Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia. Leuk Lymphoma 1998, 31:167-175.
13. Sahara N., Ohnishi K., Ono T., et al. Clinicopathological and prognostic characteristics of CD33-positive multiple myeloma. Eur J Haematol 2006, 77:14-18.
14. Liebisch P., Eppinger S., Schopflin C., et al. CD44v6, a target for novel antibody treatment approaches, is frequently expressed in multiple myeloma and associated with deletion of chromosome arm 13q. Haematologica 2005, 90:489-493.
15. Bataille R., Jego G., Robillard N., et al. The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy. Haematologica 2006, 91:1234-1240.
16. Swerdlow S.H., Campo E., Harris N.L., et al. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, IARC Press, Lyon, France.
17. Johnsen H., Bogsted M., Klausen T.W., et al. Multiparametric flow cytometry profiling of neoplastic plasma cells in multiple myeloma. Cytometry 2010, 78B:338-347.
18. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003, 121:749-757. Anonymous.
19. Perez-Persona E., Vidriales M.B., Mateo G., et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007, 110:2586-2592.
20. Paiva B., Vidriales M.B., Mateo G., et al. The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients. Blood 2009, 114:4369-4372.
21. Paiva B., Almeida J., Perez-Andres M., et al. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry 2010, 78B:239-252.
22. Seegmiller A.C., Xu Y., McKenna R.W., Karandikar N.J. Immunophenotypic differentiation between neoplastic plasma cells in mature B-cell lymphoma vs plasma cell myeloma. Am J Clin Pathol 2007, 127:176-181.
23. Treon S.P., Pilarski T.M., Belch T.R., et al. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother 2002, 25:72-81.
24. Kumar S., Kimlinger T.K., Lust J.A., Donovan K., Witzig T.E. Expression of CD52 on plasma cells in plasma cell proliferative disorders. Blood 2003, 102:1075-1077.
25. Ocio E.M., Mateos M.V., Maiso P., Pandiella A., San-Miguel J.F. New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol 2008, 9:1157-1165.
26. Perez-Persona E., Vidriales M.B., Mateo G., et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007, 110:2586-2592.
27. Perez-Persona E., Mateo G., Garcia-Sanz R., et al. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Br J Haematol 2010, 148:110-114.
28. Jerez A., Ortuno F.J., Osma M.D., et al. Bone-marrow immunophenotypic analysis allows the identification of high risk of progression and immune condition-related monoclonal gammopathy of undetermined significance. Ann Med 2009, 41:547-558.
29. Raja K.R., Kovarova L., Hajek R. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. Br J Haematol 2010, 149:334-351.
30. Bataille R., Pellat-Deceunynck C., Robillard N., Avet-Loiseau H., Harousseau J.L., Moreau P. CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis. Leuk Res 2008, 32:379-382.
31. Moreau P., Robillard N., Avet-Loiseau H., et al. Patients with CD45 negative multiple myeloma receiving high-dose therapy have it shorter survival than those with CD45 positive multiple myeloma. Haematologica 2004, 89:547-551.
32. Hundemer M., Klein U., Hose D., et al. Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14). Bone Marrow Transplant 2007, 40:1033-1037.
33. Rawstron A., Barrans S., Blythe D., et al. Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression. Br J Haematol 1999, 104:138-143.
34. Sahara N., Takeshita A., Shigeno K., et al. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br J Hematol 2002, 117:882-885.
35. San Miguel J.F., Garcia-Sanz R., Gonzalez M., Orfao A. DNA cell content studies in multiple myeloma. Leuk Lymphoma 1996, 23:33-41.
36. San Miguel J.F., Garcia-Sanz R., Gonzalez M., et al. A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood 1995, 85:448-455.
37. Pope B., Brown R., Gibson J., Joshua D. The bone marrow plasma cell labeling index by flow cytometry. Cytometry 1999, 38:286-292.
38. San Miguel J.F., Garcia-Sanz R., Gonzalez M., Orfao A. Immunophenotype and DNA cell content in multiple myeloma. Baillieres Clin Haematol 1995, 8:735-759.
39. Kapoor P., Kumar S., Fonseca R., et al. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 2009, 114:518-521.
40. Caraux A., Klein B., Paiva B., et al. Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138+ plasma cells. Haematologica 2010, 95:1016-1020.
41. Nowakowski G.S., Witzig T.E., Dingli D., et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood 2005, 106:2276-2279.
42. Billadeau D., Van Ness B., Kimlinger T., et al. Clonal circulating cells are common in plasma cell proliferative disorders: a comparison of monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and active myeloma. Blood 1996, 88:289-296.
43. Chandesris M.O., Soulier J., Labaume S., et al. Detection and follow-up of fibroblast growth factor receptor 3 expression on bone marrow and circulating plasma cells by flow cytometry in patients with t(4;14) multiple myeloma. Br J Haematol 2007, 136:609-614.
44. Rawstron A.C., Owen R.G., Davies F.E., et al. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br J Haematol 1997, 97:46-55.
45. Dingli D., Nowakowski G.S., Dispenzieri A., et al. Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system. Blood 2006, 107:3384-3388.
46. Kopp H.G., Yildirim S., Weisel K.C., Kanz L., Vogel W. Contamination of autologous peripheral blood progenitor cell grafts predicts overall survival after high-dose chemotherapy in multiple myeloma. J Cancer Res Clin Oncol 2009, 135:637-642.
47. Owen R.G., Johnson R.J., Rawstron A.C., et al. Assessment of IgH PCR strategies in multiple myeloma. J Clin Pathol 1996, 49:672-675.
48. Zhao X., Huang Q., Slovak M., Weiss L. Comparison of ancillary studies in the detection of residual disease in plasma cell myeloma in bone marrow. Am J Clin Pathol 2006, 125:895-904.
49. Liu H., Yuan C., Heinerich J., et al. Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study. Leuk Lymphoma 2008, 49:306-314.
50. Paiva B., Vidriales M.B., Cervero J., et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008, 112:4017-4023.
51. Rawstron A.C., Davies F.E., DasGupta R., et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 2002, 100:3095-3100.
52. Cannizzo E., Bellio E., Sohani A.R., et al. Multiparameter immunophenotyping by flow cytometry in multiple myeloma: the diagnostic utility of defining ranges of normal antigenic expression in comparison to histology. Cytometry B Clin Cytom 2010, 78:231-238.